Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Biotech industry readies for " Pharma M&A Spree"

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Dec 11, 2024 4:56pm

43 Views

Post# 36357620

RE:RE:Biotech industry readies for " Pharma M&A Spree"

December 04, 2024 - Ropes & Gray attorneys, who are back from sponsoring the Nov. 19-21 Jefferies London Healthcare Conference, Europe’s largest healthcare-dedicated conference, hosted a fireside chat that explored how to align incentives and drive value creation in biotech transactions.

Panelists included : Jamie Heath, Chief Financial Officer of Apollo Therapeutics; John McDonald, Corporate Vice President, Global Head of BD and M&A at Novo Nordisk; Nigel Sheail, Partner at Versant Ventures; and Monika Vnuk, Global Head of Partnering and BD at Sanofi, who discussed the following:

Optimizing value remains a priority in dealmaking. While the biotech transaction landscape saw improved financing conditions and increased M&A activity in 2024, tension remains around valuations. This is particularly true for late-stage assets, which are highly competitive and demand premiums. Companies are focusing on reaching value inflection points and tailoring deal structures to optimize value, with a notable trend toward milestone-based payments rather than large upfront commitments.
Deal structure rests on an asset’s stage of development and the expertise required. Licensing and collaboration deals are preferred when the science needs to mature and leverage the distinct capabilities of each partner, while acquisitions are often chosen for value optimization and when a single decision-maker is needed. Some panelists are cautious about option deals and prefer substantial upfront investments to mitigate long-term royalty obligations.
Biotech and cross-border M&A should be active in 2025. The biotech M&A landscape is poised for growth in 2025, driven by large biopharma companies that seek to fill pipeline gaps and capitalize on improved economic conditions. Cross-border M&A also remains active, with particular interest in jurisdictions like China. However, challenges such as regulatory scrutiny, geopolitical tensions, and the need for strategic alignment will continue to influence dealmaking decisions.